There are two reasons for this: first, both PD-L1 expression and TMB, the two major biomarkers for immunotherapy, are significantly higher in lung squamous carcinoma than lung adenocarcinoma; second, previous studies reported the majority of genomic alterations are distinct between squamous and adenocarcinoma NSCLC since they have different origins (26, 27). The gene discussed is CD274; the disease is non-small cell lung carcinoma.